FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond

On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non‐small cell lung cancer (mNSCLC) whose tumors express programmed death‐ligand 1 (PD‐L1) as determined by an FD...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Pai‐Scherf, Lee, Blumenthal, Gideon M., Li, Hongshan, Subramaniam, Sriram, Mishra‐Kalyani, Pallavi S., He, Kun, Zhao, Hong, Yu, Jingyu, Paciga, Mark, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2017
Matèries:
Regulatory Issues: FDA
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679831/
https://ncbi.nlm.nih.gov/pubmed/28835513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0078
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars